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Zusammenfassung
Lungenkrebs trägt einen großen Anteil an der weltweiten Krankheitslast und gehört zu den häufigsten
krankheitsbedingten Todesursachen. Die Erkrankung tritt in unterschiedlichen Histologien auf, welche
unterschiedliche Prognosen und Therapieoptionen implizieren. Bei der Mehrheit der Patienten wird der
Lungenkrebs erst in einem späten Stadium festgestellt, das mediane Erkrankungsalter liegt bei ca. 70
Jahren. Im frühen Stadium bestehen bei Durchführung einer Operation gute Heilungschancen. Im
fortgeschrittenen Stadium ist meist nur eine Chemotherapie, oft kombiniert mit einer Bestrahlung und eher
palliativem Ansatz, möglich. Aufgrund der hohen Mortalität der Erkrankung spielt die terminale Phase eine
große Rolle, hier liegt der Fokus auf der Beibehaltung der Lebensqualität und der Sterbebegleitung. Vor
diesem Hintergrund zielt der im Jahr 2008 ins Leben gerufene Nationale Krebsplan darauf ab, allen
Krebspatienten in Deutschland, unabhängig von ihrem Geschlecht, Alter, Wohnort oder anderen
Gegebenheiten, denselben Zugang zu effektiver, standardmäßiger aber auch innovativer, Krebstherapie zu
ermöglichen.
Ziel dieser Arbeit ist es, anhand von Krankenkassendaten die aktuelle Versorgungssituation von
Lungenkrebspatienten in Deutschland abzubilden und im Einklang mit den Zielen des Nationalen
Krebsplanes, möglicherweise vorhandene Versorgungsunterschiede aufzudecken und benachteiligte
Patientengruppen zu identifizieren. Hierzu wird eine Kohorte von ca. 17.500 Lungenkrebspatienten
(diagnostiziert in 2009) aus Daten des Wissenschaftlichen Institut der AOK (WIdO), identifiziert. Diese
Patienten werden bezüglich verschiedener Versorgungssituationen und in unterschiedlichen
Patientengruppen deskriptiv und unter der Zuhilfenahme multivariabler Analysemethoden miteinander
verglichen.
Die Untersuchungen zeigen, dass anders als bei der Ausgestaltung der Krebstherapie an sich, die Betreuung
in der letzten Lebensphase unabhängig von einem eher städtischen oder eher ländlichen Wohnort ist.
Faktoren die einen Einfluss auf die Leistungsinanspruchnahme am Lebensende haben, hängen meist mit
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einer vorherigen Tumorbehandlung, Komorbiditäten und dem Alter der Patienten zusammen. Das
Geschlecht und das Tumorstadium haben einen signifikanten Einfluss auf die unterstützende Behandlung
in der Lebensendphase.
Die Ergebnisse dieser Untersuchung zeigen auch, dass ein Großteil der Lungenkrebspatienten in
Deutschland im Krankenhaus verstirbt. Faktoren, die mit einem vorherigen Krankenhausaufenthalt bzw.
einer vorherigen Behandlung im Krankenhaus und Komorbiditäten zusammenhängen, erhöhen die
Wahrscheinlichkeit im Krankenhaus zu versterben. Wird ein Patient hingegen frühzeitig ambulant palliativ
betreut, ist die Wahrscheinlichkeit im Krankenhaus zu versterben geringer. Zu bedenken ist hierbei, dass
ein Versterben im Krankenhaus mit signifikant höheren Ausgaben für das Krankenversicherungssystem
verbunden ist.
Die Mehrheit der Lungenkrebspatienten wird erst im Alter von über 65 Jahren diagnostiziert und unsere
vorherigen Untersuchungen zeigen, dass das Alter auch einen Einfluss auf die Behandlung zum Lebensende
hat. Eine weitere Untersuchung zeigt, dass sich sowohl in der Behandlung des Tumors selbst, als auch in
der Schmerztherapie und der Gabe von Antidepressiva ein signifikanter altersabhängiger Unterschied
zulasten der älteren Patienten ergibt.
Zusammenfassend unterstreicht die vorliegende Arbeit die Wichtigkeit des nationalen Krebsplanes und die
hiermit in Verbindung stehende Notwendigkeit zur Verbesserung der Lungenkrebsversorgung. Zudem
werden ältere Patienten als eine wichtige Personengruppe herausgestellt, die einerseits besonders stark
von der Erkrankung betroffen ist und andererseits nicht immer ausreichend versorgt wird. In diesem
Zusammenhang ist eine weitere wichtige Implikation dieser Arbeit, dass die frühzeitige und stärkere
Einbindung der Palliativmedizin in die Lungenkrebsbehandlung ein wichtiger Ansatz für eine effiziente,
gleichmäßige und gerechte Versorgung ist.
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Lung cancer is a leading cause for morbidity and mortality worldwide. It presents in different histologies
with differing prognosis and treatment options. A majority of lung cancer patients is diagnosed in an
advanced stage and at a median age of around 70 years. The treatment option for early stage patients is
lung cancer resection with curative intent. Patients with advanced stage are mostly treated with
chemotherapy, often alongside radiotherapy, mostly focused on prolonging life and relief of symptoms. As
mortality in lung cancer patients is high, the terminal phase is of great importance. The primary aim of
therapy in this phase is maintaining quality of life and providing support in the last days of life. Therefore,
in 2008 the national cancer plan was introduced in order to set goals for cancer care in Germany. The main
fields of action in the national cancer plan are to provide effective and innovative, state-of-the art cancer
care for all cancer patients in Germany, irrespective of age, gender, residence area and other basic
characteristics.
The aim of this thesis is to assess lung cancer care in Germany using real world evidence from claims data.
In particular, in line with the goals set in the national cancer plan, the aim is to identify possible inequity in
cancer care or vulnerable patient groups. Using claims of around 17500 lung cancer patients (diagnosed in
2009) provided by WIdO the scientific institute of the AOK statutory health insurance (SHI) funds, in this
thesis these patients are analyze in different healthcare settings and comparisons of healthcare provision
in different patient groups are made, using descriptive and multivariable analysis methods.
The analyses show that, other than general cancer care, end-of-life care does not differ depending on the
place of residence of the patient. Factors that do influence end-of- life care are aspects relating to prior
anticancer treatment, comorbidities, and age. In addition, gender and stage of the disease at the time of
diagnosis are significantly associated with supportive care in the terminal phase.
The results show that a large proportion of lung cancer patients die in a hospital setting. Factors that are
associated with inpatient death mostly relate to prior contacts with the hospitals like prior hospitalizations
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and treatment of the tumor or comorbidities. Factors that lower the likelihood of inpatient death relate to
access to care settings, which are more focused on palliation than hospitals. Expenses for the health
insurance fund are significantly higher for patients with inpatient death.
Age plays an important role in lung cancer as a majority of patients is diagnosed when they are 65 years
and older. Additionally, age was identified as an important factor for end-of-life care. Therefore, it was
assessed whether there are inequities in lung cancer care between younger and elderly patients. The
results suggest that there is an age-dependent disparity in the frequency of anti-tumor treatment and in
supportive care provided to young and elderly patients.
This thesis highlights the importance of the national cancer plans and efforts to improve lung cancer care
in Germany. Additionally, it identifies elderly patients as a patient group that on the one hand is most
vulnerable to the disease and, for whom on the other hand therapy not always fits their needs. In line with
that, the thesis suggests that a bigger focus on, and an earlier integration of palliative care could be a crucial
step to provide more equity in lung cancer care.
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1.1. Epidemiology and Etiology
Across all types of cancer, in 2014, lung cancer had the second highest incidence in men and the third
highest incidence in women in Germany [1]. Incidence rates in 2014 ranged from 57.2 per 100,000 in men
and 28.9 per 100,000 in women [2]. Although incidence rates are stable in men and are even expected to
decrease in the coming years, numbers in females are still on the rise [1]. Further, lung cancer was the
fourth leading cause of death in Germany in 2015 [3], it accounted for the highest proportion of cancer-
related deaths in total and in men, and the second highest in women [3]. Relative 5-year survival rates are
around 16 to 21 % in males and females [4]. Lung cancer mostly develops at a higher age, with median age
at diagnosis ranging between 68 and 70 years in developed countries [1, 5, 6].
The main risk factor for lung cancer is smoking. In men, 9 out of 10 lung cancer cases, and in women at
least 6 out of 10 lung cancer cases are attributable to active smoking [1]. Passive smoking also increases
the risk. There are two main types of lung cancer, small cell lung cancer (SCLC) which makes up around 10%
to 15% of all lung cancers, and non-small lung cancers (NSCLC) which makes up around 80% to 85% [7].
NSCLC presents in several subtypes. Adenocarcinomas represent around 40% of all lung cancer cases,
squamous cell carcinoma around 25% to 30%, and large cell carcinomas about 10% to 15% [7]. In NSCLC,
staging according to the Union for Cancer Control (UICC) criteria includes stages 0, and I to IV, with
substages Ia, Ib, II2, IIb, IIIa, IIIb, IIIc, and IVa and IVb [8]. Although the UICC criteria are also used in SCLC, a
more commonly used definition is the Veterans Administration classification system [9], classifying the
cancer by very limited, limited, and extensive disease. A study conducted across several European countries
and Canada found that almost 70% of patients with SCLC are diagnosed with extensive disease [10]. In
NSCLC the proportion diagnosed with advanced disease is around 50% [10] . According to data of cancer
registries across Germany, in 2011 13% of lung cancer (SCLC and NSCLC) patients were diagnosed in stage
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I, 8% in stage II, 23% in stage III and 55% of patients was diagnosed in stage IV [11]. The delay in diagnosis
can in part be explained by a low and unspecific symptom load in the beginning of the disease [12]. It is
also a major reason for the low 5-year survival rates, as potentially curative therapy options are often only
available for early stage disease [8].
1.2.  Treatment
Treatment options in lung cancer are highly dependent on the stage and the type of cancer. Additionally,
the general condition of the patient including comorbidities are relevant factors in treatment decisions. A
higher age alone should not be the sole reason to not pursue one of the treatments [8].
Therapies include surgical resection of the tumor, radiotherapy, cytostatic chemotherapy, and therapy with
targeted agents, monoclonal antibodies and immunotherapy. In SCLC, tumor resection is often not
indicated, as this type of cancer is generally fast growing and a complete resection is mostly not possible.
Therefore, patients suffering from SCLC are mainly treated with chemotherapy [8]. In early stages of NSCLC
when the tumor sizes are still small and the cancer has not spread to other parts of the body (mainly stages
I, II, and IIIa), a resection of the tumor is the treatment of choice [8]. If a surgical resection of the tumor is
possible, the most common approach is a lobectomy [13], which means that one or more lobes of the lung
are resected. Lobectomy can be performed either thoracoscopic or as thoracotomy. Studies have shown
that thoracoscopic lobectomy is associated with less postoperative pain, fewer complications, less surgical
morbidity and equal or better long-term survival than thoracotomy [14-18]. Additionally, our own research
showed that 3-year lung cancer-specific costs are significantly lower for thoracoscopic compared to open
lobectomy from the perspective of German statutory health insurance (SHI) funds [19]. As a large part of
lung cancer patients are not eligible for a resection, chemotherapy plays a major role in treatment. But also
in patients with NSCLC who have undergone a resection of the tumor, often adjuvant chemotherapy is
administered, sometimes accompanied by radiotherapy [8]. For all patients with non-resectable tumors
12
Chapter 1 General introduction
chemotherapy, often in combination with radiotherapy, is used for treatment. After years without a major
breakthrough in therapy, treatment strategies with targeted therapies and immunotherapy have been
recently approved in the treatment of NSCLC. Some of the targeted agents show promising results in
second-line, third-line, and even in first-line therapy in patients with advanced stage NSCLC. These agents
have shown to significantly improve progression free survival [20-28], cause less toxicity [23, 25-27], and
show better quality-of-life [20-22, 28] compared to cytostatic chemotherapy. However, targeted agents
are most effective in patients with certain mutations so-called driver mutations, and only around 13-40%
of NSCLC patients have driver mutations for which a drug has already been approved [29, 30]. Regarding
immune therapy, according to a recent study from the USA around 21.5% of patients with NSCLC could be
eligible for therapy with immune checkpoint-inhibitors [31], which have shown survival benefits compared
to cytostatic chemotherapy in several randomized controlled trials [32].
1.3.  Treatment intent and treatment phases
In general, lung cancer is defined by different disease phases with differing treatment intents. In the
beginning, the intent of therapy is to cure the patient of the disease. This phase is characterized by patients
with very limited and limited disease in SCLC, and stages I, II, and IIIa, in NSCLC. In this phase, if possible,
surgical resection is performed with curative intent. In SCLC 3-year survival rates in resected patients range
from 50-70% in stage I N0 to 30-40% in stage II N1 and 20% in stage II N2 [8, 33]. In NSCLC 5-year survival
for resected patients is 69% to 89% in stage Ia [34], 52% to 75% in stage Ib [35], 45% [34] to 52% [35] in
stage IIa, 33% in stage IIb [34] and 24% [34] to 44% [35] in stage IIIa. When a curative surgical resection is
not indicated, therapy intent in both SCLC and NSCLC is palliative and defined by the goal to prolong survival
and relieve symptoms (stage IIIb and IV). Compared to best supportive care alone, classical chemotherapy
alongside best supportive care results in a 9% higher 1-year survival [36]. When a targeted therapy or
immune therapy is indicated and prescribed, this can result in significantly lower hazard ratios regarding
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progression free survival compared to classical chemotherapy [20-28]. Symptom relief in this phase of the
disease mainly refers to relief of dyspnea and pain, but also psycho-oncological aspect should be addressed
[8]. The terminal phase, which is closely linked with the second phase, is characterized by a focus on
maintaining quality of life and providing end-of-life [8]. According to treatment guidelines in this phase only
measures that relate to symptom control should be applied [8].Quality measures of end-of-life include
place of death (inpatient death unfavorable) and hospitalizations close to death, but also late onset of
palliative care and chemotherapy closely before death [37-39]. In general, studies show that an early
integration of palliative care into routine care can prolong life while maintaining a good quality of life [40-
42].
1.4. Lung cancer care in Germany
To ensure adequate provision of cancer care in Germany as described above, in 2008 the German
government defined goals concerning cancer care in the national cancer plan (Nationaler Krebsplan). The
national cancer plan includes four key fields of action including several sub goals. The first field of action
relates to cancer prevention, the second involves further development of structures in oncological health
care, the third ensures provision of efficient oncological treatment, and the fourth has an emphasis on
strengthening patient orientation. Prevention of lung cancer involves on the one hand initiatives to
strengthen tobacco control, campaigns to stop smoking or prevent people to start smoking, as well as
introducing non-smoking. On the other hand, it involves programs for lung cancer screening. So far, there
is no population based screening program in Germany, however the guideline allows yearly low-dose CT
scans for asymptomatic patients at risk [8]. The first goal of field of action number two is to have all cancer
patients receive high quality care, notwithstanding their age, gender, origin, place of residence or insurance
status. In line with this, a process of certifying hospital as cancer centers was introduced. These centers
have to fulfill several criteria in order to receive accreditation as certified centers and have to maintain
14
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these standards over time. Until the end of 2017, there were 49 certified lung cancer centers in Germany.
The main aim in field of action three is to ensure that all patients have a fair and fast access to innovative
and efficient cancer therapies. This includes a quick translation of results from basic research to real world
treatment of patients. Patient orientation can be strengthened by offering comprehensive and easily
accessible information to patients and their relatives. Additionally, communication skills of all service
providers involved should be trained regularly, and patients should be included actively in treatment
decisions.
1.5. Health Services Research and claims data
According to the German Centers for Health Research, health services research (HSR) represents the fourth
pillar of health research besides basic research, pre-clinical research and clinical research [43]. It
investigates how basic and clinical research is translated into routine care and how policy changes like the
introduction of the national cancer plan affect everyday medical care. In line with the goals of the national
cancer plan, additionally, it aims at detecting over- and underprovision of care. Data used in this kind of
research mainly comes from physician records, hospital records, and claims of SHI funds.
Claims data, also called administrative data or secondary data, refer to data that is collected routinely by
service providers and SHI funds mainly for the purpose of reimbursement. Analyses involving claims data
often focus on access to healthcare e.g. disparities in treatment [44], quality of healthcare [44], but also
the evaluation of interventions and policy changes [45].
A major challenge when analyzing claims data relates to the lack of clinical information, as information in
claims data are restricted to the needs of reimbursement. For example, in lung cancer claims data does not
provide direct information about the histology of the cancer or the stage of the cancer at the time of
diagnosis. This information can only be derived indirectly by using diagnoses of metastases or procedural
codes for therapies. Another weakness of claims data refers to underreporting and incorrect data. If a
15
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specific test or diagnostic code is not relevant for reimbursement purposes it is less likely to be reported.
Further, data can be entered incorrect e.g. by the administrative clerk.
Although there are some challenges to using claims data, they are a powerful tool to generate real world
evidence in medical science. One major advantage of claims data is the aspect of external validity [46]. In
Germany, around 86% of the population is insured through a SHI fund. Law regulates insurance
contributions and healthcare services covered by the SHI and patient clientele differs only slightly between
different SHI funds [47]. Therefore, analyzing German SHI claims can provide a comprehensive overview of
nationwide routine healthcare practices and results can be generalized to the whole population.
Additionally, compared to clinical trials these data help to study groups that are generally more difficult to
observe because they are often not included in clinical trials, like children or elderly patients [48].
Therefore, it is possible to analyze if evidence from clinical trials and health policies are implemented in the
broad population and whether there are disparities between patient groups regarding if and how this
evidence and policies are administered. Furthermore, sample sizes in claims data analyses are typically
large therefore, rare diseases, rare complications, and rare outcomes can be studied appropriately.
The dataset used in the analyses of the three papers included in this thesis contained anonymized health
insurance claims for 17478 patients diagnosed with lung cancer in 2009. The dataset was provided by WIdO,
the scientific institute of the AOK SHI funds, which covers around 30% of the German resident population.
Basic data contained month and year of birth, month and year of death (if applicable), sex, and care level
as well as nursing home residence status over the course of the disease. Additionally, it included claims for
hospitalizations, outpatient hospital visits, outpatient physician visits, and medications.
1.6. Objectives, and contents of this dissertation
The main objective of this dissertation is to study lung cancer care in Germany using claims data. In
particular, relating to the goals in fields of action two defined in the national cancer plan, the thesis aims
16
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to detect possible differences in lung cancer care between geographical regions and across patient
populations with different characteristics. In consequence, the information gathered in this thesis can be
used to identify aspects of care that need improvement and patient groups that are more vulnerable, or
until now, do not get the best care to fit their needs.
Article 1 aims at detecting differences relating to geographical residence (rural or urban) in end-of-life care
in lung cancer patients. As laid out in chapter 1.1, mortality rates in lung cancer are high, therefore the end-
of-life phase is a phase that affects most patients during the course of the disease. As other studies found
that active lung cancer treatment differs between rural and urban areas, this analysis aims to detect
whether end-of-life care also differs according to the area of residence. Using the district types major city,
urban area, rural area and remote rural area the analysis compares a variety of aspects of end-of-life care
relating to healthcare utilization and supportive care. There were no differences relating to geographical
residence of the patients, therefore the results reject the hypothesis of regional inequality in end-of-life
care. Instead, the results show that trigger factors for high and low utilization of healthcare are mostly age,
comorbidities, and prior anticancer treatment. Supportive care is mostly associated with gender and the
stage of the disease at the time of diagnosis.
The analysis in article 1 also shows that, compared to other countries, quality indicators of end-of-life care
have room for improvement in Germany. In particular, the majority of lung cancer patients in Germany die
in a hospital setting, whereas in the USA only around 20% of patients do [49]. Previous research has found
that irrespective of a cancer diagnosis, there is a preference for dying at home or in a hospice [50, 51].
Therefore, article 2 aims to identify factors associated to inpatient death in German lung cancer patients.
Using a least absolute shrinkage and selection operator (LASSO) selection model, the analysis identifies
factors relating to an increased and decreased likelihood of inpatient death. Factors associated with a
higher likelihood of inpatient death are often related to previous contacts with hospitals like prior
hospitalizations and treatment of the tumor or comorbidities. Factors associated with a lower likelihood of
17
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inpatient death are related to access to care settings, which are more focused on palliation than hospitals.
Additionally, expenses for the health insurance fund are significantly higher for patients with inpatient
death. These findings suggest that a more thorough implementation of tools like palliative care might help
patients to make self-determined decisions relating to their place of death.
Article 3 focuses on differences in therapy relating to the patients’ age. Results from article 1 suggest that
end-of-life care is associated directly with the age of the patient. As lung cancer is most commonly
diagnosed in elderly patients with a median age of diagnosis of around  68-70 years in developed countries
[1, 5, 6], these patients make up the majority of lung cancer cases. Therefore, this article studies differences
in active tumor therapy, diagnostic measures, palliative care, and costs between non-elderly (≤ 65 years)
and young-old (65-74 years), middle-old (75-84 years), and old-old (≥ 85 years) patients. Results show that
the likelihood to receive any tumor-directed treatment is significantly associated with age. Elderly lung
cancer patients receive significantly fewer resections and radiotherapy or antineoplastic therapy.
Additionally, older patients are less likely to receive structured palliative care and increasing age is
associated with reduced quotas for outpatient treatment with opioids and antidepressants. These results
suggest the existence of an age-dependent care disparity with potential undertreatment of elderly patients.
Adjustments to public health policies seem to be urgently needed to support equal access to care.
In conclusion, the three articles of this thesis highlight the importance of the national cancer plans and
efforts to improve lung cancer care in Germany. It shows that end-of-life care is provided indiscriminately
across Germany, without disadvantages for patients from rural areas. However, the research identifies
elderly patients as an important patient groups that, on the one hand is most vulnerable to the disease,
and on the other hand suffers from potential undertreatment. In line with that, the thesis suggests that a
bigger focus on, and an earlier integration of palliative care could be a crucial step to provide more equity
in lung cancer care.
18
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1.7. Individual contribution of the author
The author of this thesis has contributed substantially to the concept of all included articles and the
involved study question, and prepared the datasets for all analysis. Additionally, she performed the
statistical analysis for the articles 1 and 3, wrote the original manuscript for these articles, and accompanied
the publication process as the corresponding author. She has supervised the Master thesis, which formed
the basis for article 2, and was the main contributor to editing and reviewing this article.
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Abstract
Purpose To assess rural-urban differences in healthcare utilization and supportive care at the end-of-life in German lung cancer
patients.
Methods We identified 12,929 patients with incident lung cancer in 2009 from claims data and categorized them to four
district types (major city, urban, rural, remote rural). We compared site of death, unplanned hospitalizations, hospital days,
outpatient doctor, general practitioner (GP) and home visits, structured palliative care, therapy with antidepressants, pain
relief medication and chemotherapy, and therapeutic puncturing in the last 30 and 14 days of life using mixed models
with logistic link function for binary outcomes and log link function for count data. We adjusted all models by age, sex,
comorbidities, metastases location and presence of multiple tumors at diagnosis, survival in months, and type of tumor-
directed treatment.
Results We found significant differences in two of the outcomes measured. The likelihood of > 14 hospital days in the last
30 dayswas significantly higher in rural districts than in remote rural districts (1.27 [1.05, 1.52], p = 0.0003). The number of visits
to the GP in the last 30 days of life was significantly lower in urban districts than in remote rural districts (β = − 0.19 [− 0.32, −
0.06], p = <0.0001). No other endpoints were associated with regional differences. Triggering factors for high and low utilization
of healthcare were mostly age, comorbidities, and prior anticancer treatment.
Conclusion Healthcare utilization and supportive care did not differ significantly between different district types. Results reject
the hypothesis of regional inequity in end-of-life care of lung cancer patients in Germany.
Keywords Rurality . Quality of care . Equality . Claims data . Death . Regional differences
Introduction
Five-year survival rates of lung cancer patients are one of the
lowest across all types of cancer, at around 16–20% [1].
Therefore, the end-of-life phase is especially important for
patients with this type of cancer. It poses one of the most
challenging phases as, on the one hand, the quality of care
and the possibility of passing away with dignity is of high
importance. On the other hand, costs and healthcare utilization
are highest in the year before death, matched only by those
right after diagnosis [2].
Studies have shown that access to general cancer care
varies between rural and urban areas, with more specialized
care centers in central cities. There are significant differences
between rural and urban areas concerning the type of onco-
logical treatment (surgery, chemotherapy, or radiotherapy) pa-
tients receive [3–5]. Travel time also has a significant influ-
ence on access to specialists and treatment [6–8], and
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furthermore poses an extra burden on patients. [9] This leads
to a fear among cancer patients and their relatives living in
rural settings of not getting the same quality of care, a fear
underlined in a review considering the perspectives of pa-
tients, family, and caregivers [10].
End-of-life care differs from general treatment as it is not
intended to be curative or to prolong life, but focuses on pain
relief and symptom control. Guidelines recommend that in the
terminal phase of lung cancer, only measures that relate to
symptom control should be applied [11]. To this point, there
have been only few studies assessing differences in end-of-life
care between rural and urban areas. Ho et al. (2011) assessed
trends in aggressiveness of end-of-life care in Canada as a
composite endpoint and found that living in a rural area was
a significant predictor for receiving aggressive care [12].
Other studies focusing on nursing home residents found that,
on the one hand, in rural areas fewer feeding tubes were used,
and the average length of hospitalizations was lower than in
urban areas, but, on the other hand, the number of hospitali-
zations and inhospital deaths were lower in urban areas
[13–15]. A study in elderly lung cancer patients found that
rural residents had fewer emergency room (ER) admissions
and a higher usage of hospice services, but more intensive care
unit (ICU) days than urban residents [16].
However, to this point, no extensive study has assessed
rural-urban differences on end-of-life care including also sup-
portive care measures specifically in lung cancer patients.
Therefore, the aim of this study was to compare differences
in healthcare utilization and supportive care at the end-of-life
between lung cancer patients from urban vs. rural areas and
see whether patients in rural areas are at a disadvantage. All
analyses were carried out using data from German statutory
health insurance companies (SHI).
Material and methods
Study design and study population
We conducted a retrospective observational study of adminis-
trative claims data in Germany. Data came from the Scientific
Institute of AOK SHI fund, covering around 30% of the
German resident population, and included patients from all
402 districts in Germany. In total, around 86% of German
citizens are insured in a SHI. Law regulates insurance contri-
butions and healthcare services covered by the SHIs. Patient
clientele differs only slightly between different SHIs. Data was
completely anonymized and according to Swart et al. [17], the
consultation of an ethics committee is not required for analysis
of this kind of data. Data included patient-level data of inpatient
and outpatient treatment costs, German International
Classification of Diseases (ICD-10-GM) codes, andOPS codes
(German Version of the International Classification of
Procedures in Medicine) from 2009 to 2012. A study popula-
tion consisting of patients with incident lung cancer in 2009
was derived previously from this dataset. A detailed description
of the methodology can be found elsewhere [18]. From the
study population, we analyzed those who had died before the
year 2013 but who had at least survived for more than 30 days
after diagnosis. We also excluded patients with missing infor-
mation about their area of residence.
Urban and rural areas
To distinguish between different types of residential areas, we
used the district types defined by the German Federal Institute
for Research on Building, Urban Affairs, and Spatial
Development for 2014, which are based on both the population
density and the proportion of the population living in large and
medium-sized cities [19]. It distinguishes four district types:
Major city: minimum 100,000 inhabitants
Urban districts: districts with minimum 50% of popula-
tion in large or medium-sized cities and population den-
sity > 150 inhabitants/km2, or districts with population
density of > 150 inhabitants/km2 when excluding large
or medium-sized cities
Rural districts with population concentrations: districts
with minimum 50% of population in large or medium-
sized cities but population density < 150 inhabitants/km2,
or districts with less than 50% of population in large or
medium-sized cities but population density > 100 inhab-
itants/km2
Remote rural districts with low population density: dis-
tricts with less than 50% of population in large or
medium-sized cities and population density < 100 inhab-
itants/km2 when excluding large or medium-sized cities
Patients in our analysis were assigned to one of the district
types according to the ZIP-code of the last known place of
residence.
Healthcare utilization and supportive care
The following outcomes concerning healthcare utilization
were compared between the four district types: site of death
by determining inpatient deaths from the discharge status of
the last hospitalization, more than one unplanned (admit sta-
tus = emergency) hospitalization in the last 30 days of life,
spending more than 14 days in the hospital in the last 30 days
of life, and number of office (all doctors and general practi-
tioner (GP)) and home visits by providers. Apart from that, we
looked at palliative and supportive care during the last weeks
of life by measuring the following: start of palliative care at
least 30 days before death (taking into account inpatient and
outpatient claims for structured palliative care measures),
2276 Support Care Cancer (2018) 26:2275–2283
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treatment with antidepressants and with structured pain relief
treatment during the last 30 days of life (indicated by outpa-
tient claims for antidepressants and WHO stages 2 or 3 pain
medication as well as inpatient claims for structured pain treat-
ment), chemotherapy treatments in the last 2 weeks of life, and
therapeutic puncturing (ascites, pleural, pericardial) in the last
2 weeks. We included chemotherapy treatment, as according
to guidelines, all treatment not relating to symptom control
should be ceased [11]. Also, palliative care is associated with
reducing chemotherapy, and quality of life has been shown to
increase with earlier onset of palliative care [20–22]. All
above treatments were identified through ICD codes, OPS
codes, and ATC codes from inpatient and outpatient records.
Covariates
Covariates for the analysis were sex, age at time of death,
comorbidities at time of diagnosis, presence of multiple tu-
mors at diagnosis, type of coded metastases at diagnosis (no
metastases, metastases in lymph nodes or other metastases),
survival after diagnosis in months, and the type of anticancer
treatment (no treatment, surgery, chemotherapy, radiothera-
py). Comorbidities and treatments were derived from inpatient
and outpatient ICD and OPS codes as well as physician fee
records.We included congestive heart failure, diabetes, chron-
ic obstructive pulmonary disease (COPD), moderate or severe
liver disease, and renal disease as they are negatively associ-
ated with survival in lung cancer and are also relevant when it
comes to the choice of lung cancer therapy [11, 23, 24].
Statistical analysis
We calculated sample characteristics, healthcare utilization,
and aspects of medical care as means and proportions in the
four groups. We used generalized linear mixed models
(GLMM) to account for cluster effects in each district by in-
cluding the district number as random intercept. To estimate
any binary indicator of medical service utilization, we used
logistic regression in the GLMM; for indicators with count
data, we used a log link function and the Poisson distribution.
Except for the outcome of chemotherapy in the last 14 days
of life where the type of anticancer treatment was left out, all
regression models were adjusted by the covariates mentioned
above. To take into account multiple testing, we used a signif-
icance threshold of α < = 0.0045 and calculated 99.55% con-
fidence intervals for all outcomes (Bonferroni adjustment
based on running 11 models).
In sensitivity analysis 1 (SA 1), we analyzed the above
aspects in a subgroup of patients that survived at least 180 days
after diagnosis, to exclude a potential bias from patients who
died suddenly due to side effects during the initial treatment
(e.g., during surgery) and therefore did not receive specific
end-of-life care.
In a second sensitivity analysis (SA 2), we only used inpa-
tient healthcare events (e.g., hospitalizations, hospital days)
with a major diagnosis of lung cancer to calculate the out-
comes. By this, we wanted to exclude a bias caused by inpa-
tient healthcare utilization due to comorbidity.
All analyses were performed using SAS 9.3 (SAS software
of the SAS System for Microsoft, Version 9.3 (c) 2002–2010
by SAS Institute Inc., Cary, NC, USA.); tables and figures
were created in Microsoft Excel and PowerPoint.
Results
Study population and unadjusted outcomes
The study population comprised 12,929 patients. A patient
flow diagram can be found in Fig. 1. In Table 1, the general
demographic information of the study population is listed in
total and in the four different district types.
The descriptive statistics of healthcare utilization and sup-
portive care across the four district types are reported in
Table 2. Concerning the percentage of patients spending more
than 14 days in the hospital in the last 30 days of life, we found
a gradient towards increasing percentages with increasing ur-
banization of the district. The number of doctor visits was
lowest in major cities, highest in urban districts, and
Fig. 1 Patient flow diagram of study population
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decreasing again with higher rurality. The results for the num-
ber of GP visits and the number of home visits were similar.
Adjusted outcomes
We found significant differences in two aspects of healthcare
utilization between the different district types; the results can
be found in Table 3. The odds ratio of spending more than
14 days in the hospital in the last 30 days of life was signifi-
cantly higher in rural districts than in remote rural districts
(1.27 [1.05, 1.52], p = 0.0003), and the number of visits to
the general practitioner (GP) in the last 30 days of life was
significantly lower in urban districts than in remote rural dis-
tricts (β = − 0.19 [− 0.32, − 0.06], p = < 0.0001. Concerning
Table 1 Sample characteristics
Total
(N = 12,929)
Major city
(N = 3488)
Urban district
(N = 4654)
Rural district
(N = 2454)
Rural district with
low population
density (N = 2333)
Mean age in years (sd) 68.8 (10.1) 68.5 (10.0) 68.4 (10.1) 69.6 (10.1) 69.5 (9.8)
Male gender N (%) 9253 (71.6) 2323 (66.6) 3323 (71.4) 1848 (75.3) 1759 (75.4)
Diabetes mellitus N (%) 1832 (14.2) 480 (13.8) 619 (13.3) 391 (15.9) 342 (14.7)
Renal disease N (%) 294 (2.3) 84 (2.4) 93 (2.0) 68 (2.8) 49 (2.1)
Liver disease N (%) 225 (1.7) 70 (2.0) 79 (1.7) 38 (1.6) 38 (1.6)
COPD N (%) 6563 (50.8) 1886 (54.1) 2280 (49.0) 1235 (50.3) 1162 (49.8)
Congestive heart failure N (%) 4638 (35.9) 1150 (33.0) 1597 (34.3) 962 (39.2) 929 (39.8)
Multiple tumors at diagnosis N (%) 1904 (14.7) 490 (14.1) 723 (15.5) 343 (14.0) 348 (14.9)
Metastases at diagnosis N (%) 7845 (60.7) 2144 (61.5) 2807 (60.3) 1485 (60.5) 1409 (60.4)
Mean survival after diagnosis in months (sd) 11.0 (9.6) 11.0 (9.6) 10.9 (9.6) 11.3 (9.9) 10.5 (9.2)
Treatment
No treatment N (%) 2392 (18.5) 612 (17.6) 850 (18.3) 463 (18.9) 467 (20.0)
Chemotherapy N (%) 8857 (68.5) 2444 (70.1) 3238 (69.6) 1642 (66.9) 1533 (65.7)
Surgery N (%) 1428 (11.0) 398 (11.4) 526 (11.3) 286 (11.7) 218 (9.3)
Radiotherapy N (%) 6310 (48.8) 1748 (50.1) 2290 (49.2) 1171 (47.7) 1101 (47.2)
Means and proportions of sample characteristics broken down by district type
sd, standard deviation; COPD, chronic obstructive pulmonary disease
Table 2 Unadjusted proportions and means of healthcare utilization and supportive care
Total
(N = 12,929)
Major city
(N = 3488)
Urban district
(N = 4654)
Rural district
(N = 2454)
Rural district with
low population
density (N = 2333)
Mean number of doctor visits in last 30 days 5.3 4.9 5.7 5.5 5.1
Mean number of GP visits in last 30 days 2.9 2.4 3.1 3.0 3.0
Mean number of home visits in last 30 days 1.7 1.6 1.8 1.7 1.7
Proportion in %
More than 1 unplanned hospital visit in last 30 days 9.6 11.0 8.8 9.4 9.6
Spending more than 14 days in the hospital in last 30 days 42.8 46.5 42.1 40.9 40.5
Death in acute care hospital 55.8 57.3 55.0 54.8 56.3
Chemotherapy in last 14 daysa 18.6 18.5 18.9 17.5 19.2
First palliative care contact at least 30 days before death 16.3 15.3 16.5 15.8 17.6
Prescription of antidepressants in last 30 daysb 10.5 9.78 11.56 10.68 9.52
Structural pain medication in last 30 days 33.34 31.79 33.05 35.09 34.42
Therapeutic puncture in last 14 days 3.5 2.9 3.7 3.3 4.2
Unadjusted proportions and means of healthcare utilization and medical care in relation to district type
GP, general practitioner
a Calculated only for patients that were treated with chemotherapy over the course of the disease (N = 3941)
b Calculated for patients without a prior diagnosis of depression (N = 11,040)
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all other measures of healthcare utilization and supportive
medical treatment, we did not find significant differences.
As the differences in healthcare utilization and supportive
care of the adjusted analysis were mostly not significantly
associated with the district type, we looked a bit further into
the covariates that did have a significant influence in the mul-
tivariate model. A summary of the significant covariates and
the direction of their influence can be found in Table 4.
Concerning outpatient healthcare utilization, male gender
and comorbidities were significantly associated with lower
numbers of doctor visits. Age was associated with a higher
number. A higher inpatient healthcare utilization was mostly
driven by comorbidities and all types of anticancer treatments
during the course of the disease. Older age and longer survival
after diagnosis were associated with less inpatient healthcare
use. Supportive care was given to males significantly less
often than to females. And a lower stage of the disease at
diagnosis was associated with receiving more structured sup-
portive care measures.
As quality of care also relates to survival, in an additional
analysis, we compared the adjusted length of survival in
months between the four district types and did not find any
significant differences.
Sensitivity analysis
When we excluded patients who did not survive for at least
180 days after diagnosis in SA 1, the study population included
7707 patients. By and large, the effects in this sensitivity anal-
ysis remained stable. We found several odds ratios with a re-
versed direction; however, all were non-significant in the com-
plete sample as well as in the subsample. Concerning GP visits,
the difference between urban and remote rural areas was not
significant anymore, but the difference between major cities
and the reference group was, with fewer visits in major cities.
When we only included hospitalizations with amajor diagnosis
of lung cancer in SA 2, the effects of comorbid conditions were
not significant anymore; prior anticancer treatment remained as
the main triggering factor. Results from the sensitivity analysis
can be found in Online Resources 1 to 3.
Discussion
This study sought to evaluate possible differences between
end-of-life care in urban and rural areas of Germany to see if
patients in rural areas are at a disadvantage concerning their
quality of end-of-life care. Our results show that the utilization
of healthcare services and supportive care does not differ sig-
nificantly depending on the area of residence. We only found
two aspects with significant differences. Patients in urban dis-
tricts tended to have fewer GP visits, and patients in rural
districts were less likely to spend more than 14 days in the
hospital in their last weeks of life than in remote rural districts
with low population density. In addition, in the sensitivity
analysis, we only found a few significant differences. This
Table 3 Adjusted odds ratios and parameter estimates of healthcare utilization and supportive care
Major city vs. rural district
with low population density
Urban district vs. rural district
with low population density
Rural district vs. rural district
with low population density
β CI P value β CI P value β CI P value
No. of doctor visits in last 30 days 0.07 [− 0.04, 0.18] 0.06 − 0.07 [− 0.20, 0.06] 0.12 0.06 [− 0.06, 0.17] 0.16
No. of GP visits in last 30 days 0.01 [− 0.10, 0.12] 0.80 − 0.19 [− 0.32, −0.06] < 0.0001 −0.02 [− 0.14, 0.10] 0.61
No. of home visits in last 30 days 0.11 [− 0.06, 0.29] 0.07 − 0.11 [− 0.32, 0.10] 0.13 0.02 [− 0.17, 0.21] 0.76
OR CI P value OR CI P value OR CI P-value
More than 1 unplanned
hospital visit in last 30 days
1.21 [0.99, 1.48] 0.01 0.98 [0.73, 1.31] 0.82 0.90 [0.69. 1.17] 0.26
Spending more than 14 days
in the hospital in last 30 days
1.03 [0.86, 1.25] 0.62 1.06 [0.90, 1.26] 0.31 1.27 [1.05, 1.52] 0.0003
Death in acute care hospital 0.94 [0.77, 1.15] 0.40 0.92 [0.77, 1.10] 0.18 1.03 [0.84, 1.27] 0.65
Chemotherapy in last 14 daysa 0.95 [0.70, 1.27] 0.59 1.03 [0.79, 1.33] 0.76 0.89 [0.67, 1.19] 0.24
First palliative care at least 30 days before death 0.90 [0.65, 1.24] 0.33 0.88 [0.66, 1.19] 0.23 0.83 [0.59, 1.17] 0.13
Prescription of antidepressants in last 30 daysb 0.93 [0.66, 1.29] 0.51 1.18 [0.88, 1.58] 0.11 1.05 [0.75, 1.47] 0.68
Structural pain medication in last 30 days 0.85 [0.71, 1.02] 0.01 0.91 [0.77, 1.08] 0.13 1.03 [0.85, 1.24] 0.71
Therapeutic puncture in last 14 days 0.78 [0.50, 1.21] 0.11 0.87 [0.60, 1.27] 0.30 0.68 [0.44, 1.04] 0.01
Odds ratios for each district type from logistic regression of binary healthcare utilization and medical care and parameter estimates β from Poisson
regression for healthcare utilization with count data
a Calculated only for patients that were treated with chemotherapy over the course of the disease (N = 8857)
b Calculated for patients without a prior diagnosis of depression (N = 11,040)
OR, odds ratio; CI, confidence interval; GP, general practitioner
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leads to the conclusion that although access to anticancer treat-
ment might be different depending on the area of residence,
end-of-life care does not generally differ significantly. A rea-
son for this finding could be that specialists mostly carry out
anticancer care and often these specialists are centered in and
around bigger cities, whereas end-of-life care can be provided
by GPs and hospice services, which can be found in every
district type. Therefore, regional differences in end-of-life care
are not an issue in a German setting.
As the district type did not trigger differences seen in the
univariate analysis, we looked into which other covariates
mostly contributed to differences in healthcare utilization and
supportive care. Contrary to outpatient care, the utilization of
inpatient healthcare significantly decreased with increasing
age. Therefore, with increasing age, there seems to be a shift
from inpatient to outpatient end-of-life care. The opposite ef-
fect was found concerning comorbidities. Having a comorbid
condition was associated with increasing inpatient and decreas-
ing outpatient healthcare utilization. Most of the comorbidities
in the study like COPD and heart insufficiency are comorbid
conditions that can usually be handled in an outpatient setting
leading to the question whether these conditions are managed
appropriately in the outpatient sector in Germany. When we
only included hospitalizations with a major diagnosis of lung
cancer in the sensitivity analysis, the effects of comorbid con-
ditions were not significant anymore. Interestingly, prior treat-
ments with chemotherapy, radiotherapy, or lung cancer surgery
were significant indicators of inpatient treatment at the end-of-
life but in the case of prior lung cancer surgery, a predictor of
decreased outpatient treatment. This could indicate that patients
with prior hospital treatment are more likely to use hospital
services again at the end-of-life.
Concerning supportive care at the end-of-life, we found
that male gender was significantly associated with lower
use. Male patients were less likely to receive structured palli-
ative care at an earlier stage and to be treated with structured
pain medication and antidepressants. This finding is likely due
to patient preferences and different opinions regarding the
need of supportive care. A less advanced stage and longer
survival were significantly associated with a higher likelihood
of supportive care. Patients with less advanced stages at diag-
nosis have more time to prepare themselves and arrange their
living and treatment conditions at the end-of-life.
A study fromCanada using a composite endpoint of receiv-
ing at least one of the four indicators of aggressive care in
cancer patients (chemotherapy in last 14 days, more than
one ER visit, more than one hospitalization, and at least one
ICU admission in the last 30 days), found that rurality was a
significant predictor of the likelihood of experiencing one or
more of these indicators [12]. However, we cannot evaluate
the extent to which each of the single indicators was predicted
by rurality so a direct comparison to our results is not feasible.
Nayar et al. studied healthcare utilization of elderly lung
cancer patients in the last 90 days of life in 2014 [16]. They
Table 4 Predictors of healthcare utilization and supportive care from regression analysis
Male
gender Age DM LD RD
HI
COPD
Prior
Cancer
None vs.
distant mets
Lymph- node
vs. distant mets CH RT SU
Surv month
No. of doctor visits in last 30 days + (+) (−) + – (−) + + – –
No. of GP visits in last 30 days – + + – – + (−) –
No. of home visits in last 30 days – + – – – – + – –
Chemotherapy in last 14 daysa – (+) (+ ) (+)
–
More than 1 unplanned hospital
visit in last 30 days
(+) – + (+) + –
Spending more than 14 days
in the hospital in last 30 days
– (+) + + (+) + + + –
Death in acute care hospital – (+) + + + + (−) + (+) + –
First palliative care at least
30 days before death
– + + + + +
Prescription of antidepressants
in last 30 daysb
– + +
Structural pain medication in
last 30 days
– (−) (−) – + +
Therapeutic puncture in last 14 days – –
Significance (at α < 0.0045) and direction of parameter estimates from regression of healthcare utilization and supportive care. B+^ indicates increasing
number/likelihood, B–^ indicates decreased number/likelihood. Brackets indicate predictors with significance α < 0.05
a Calculated only for patients that were treated with chemotherapy over the course of the disease (N = 8857)
b Calculated for patients without a prior diagnosis of depression (N = 11,040)
DM, diabetes mellitus; LD, liver disease; RD, renal disease; HI, heart insufficiency; COPD, chronic obstructive pulmonary disease; CH, chemotherapy;
RT, radiotherapy; SU, surgery; GP, general practitioner
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found significant differences betweenmetropolitan areas com-
pared to micropolitan, rural, and rural remote areas in the
United States of America (USA). Residents of metropolitan
areas had significantly more inpatient admissions compared to
micropolitan areas and significantly fewer visits to the ER
than in all other areas. In contrast to that, we did not find a
significant difference between the likelihood of an unplanned
hospital visit between remote rural districts with low popula-
tion density and the other district types.
Other studies comparing rural-urban differences have fo-
cused on end-of-life care in nursing-home residents and in
contrast to our study found that rural residence was signifi-
cantly associated with a higher likelihood of inpatient death,
hospitalization, and a lower risk of ICU admissions [14, 15].
Despite the differences in the characteristics of the study-
populations (nursing home residents vs. all lung cancer pa-
tients), there were also some similar results to our data. In line
with a German study that compared the 5-year survival rates
of cancer and also specifically lung cancer patients between
rural and urban districts, we did not find significant differ-
ences in the length of survival [25].
Disregarding effects of the district type, compared to stud-
ies analyzing the quality of end-of-life care of cancer patients
in other countries, we found higher percentages of patients
receiving chemotherapy in the last 14 days in Germany
(19%) and in the USA (18%) [26] than in Canada (3–16%)
[12, 27] and Korea (6%) [28]. Further, the percentage of pa-
tients dying in the hospital was higher in Germany (56%)
compared to for instance the USA (20%). A reason for this
result is that in the USA, hospice care is paid for byMedicare,
and patients with a life expectancy of less than 6 months are
encouraged to visit such a facility [29].
Earle et al. developed upper benchmarks for some of the
aspects of care which we used for our study [30]. Healthcare
systems with numbers below these benchmarks would be con-
sidered as not providing aggressive or intense treatment at the
end-of-life. Compared to these benchmarks, the number of
unplanned hospital visits and the proportion of inpatient
deaths in our study were above the suggested upper bench-
marks. However, these benchmarks were set based on 11 re-
gions in the USA, so differences between the healthcare sys-
tems of the two countries may restrict a direct transfer of the
benchmarks to the results found in our study.
A limitation of this study is that in our data, it was not
feasible to distinguish between small cell lung cancer and
non-small cell lung cancer or to identify the stage of the dis-
ease. However, the effect of these variables on the end-of-life
care is small, and palliative treatment strategies are similar
across histology.
Also, the term district describes areas with a wide variety of
sizes (35–3000 km2) and populations (34,000–1.8 million)
[19]. In defining the four different district types, these factors
are taken into account by categorizing according to population
density and the percentage of the population living in cities, yet
this does not rule out the possibility that districts with the same
district type are not similar in terms of other influencing fac-
tors. However, by using a mixed model, we adjusted for cluster
effects in each district in order to minimize this possible bias.
Another limitation is that by using claims data, the patient
burden and preferences at the end-of-life cannot be directly
measured, and possible differences in patient-reported outcomes
cannot be analyzed. The same is true for information about the
availability and access to different care settings. Generally, inpa-
tient and outpatient hospice services are available to all citizens.
They are covered under SHI and the compulsory long-term care
insurance. Unfortunately, from the codes in our dataset, we
could only derive whether structured palliative care services
were provided but not if they were provided in a hospice or by
hospice services. Information on socioeconomic status was not
available in the dataset. However, the same as hospice services,
home care, and nursing home care are covered by SHIs and the
long-term care insurance, which is compulsory for all citizens.
Albeit, in some cases, costs for home or nursing home care can
be higher than the reimbursement. Therefore, financial reasons
can influence end-of-life care decision making; however, these
could not be assessed fully in our study.
The biggest strength of our study is the sample size of our
dataset. It covers around 30% of the German residents, and
our study population includes patients from all 402 districts in
Germany. Further, in Germany, around 86% of the population
is insured through SHIs similar to AOK, and 90–95% of all
services provided are defined by law. Therefore, our results
are generalizable to the whole German population. Another
strength is the comprehensive picture of the treatment process
that can be derived from the insurance data.
Equality in the access to high quality healthcare depending
on the area of living has been researched in different studies
[31, 32]. Concerning the end-of-life phase, to this point, there
has been little evidence presented on this topic, especially for
the case of lung cancer. Therefore, our study contributes to
forming a picture on how end-of-life care is undertaken de-
pending on the area of residence and lowers the fear of not
getting the best quality of care.
Conclusion
In contrast to studies from other countries, our results show that
lung cancer patients receive the same kind of supportive care at
the end-of-life regardless of whether they live in a big city, a
smaller town, or in the countryside in Germany. In addition,
healthcare utilization does not differ significantly between dif-
ferent area types. Triggering factors for high and low utilization
of healthcare are mostly age, comorbidities, and prior antican-
cer treatment. Receiving supportive care was mostly predicted
by male gender and the disease stage at diagnosis.
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Abstract
Background: When patients die in a hospital their quality of life is lower than when they die at home or in a
hospice. Despite efforts to improve palliative care supply structures, still about 60% of lung cancer patients die in a
hospital. Studies have examined factors related to inhospital death in lung cancer patients, yet none used data of a
representative German population, additionally including economic aspects. This study aimed to identify factors
related to inhospital death in German lung cancer patients and analysed resulting costs.
Methods: We analysed a dataset of health insurance claims of 17,478 lung cancer patients (incident 2009) with 3
year individual follow-up. We grouped patients into inhospital death and death elsewhere. Studied factors were
indicators of healthcare utilization, palliative care, comorbidities and disease spread. We used logistic regression
models with LASSO selection method to identify relevant factors. We compared all-cause healthcare expenditures
for the last 30 days of life between both groups using generalized linear models with gamma distribution.
Results: Twelve thousand four hundred fifty-seven patients died in the observation period, thereof 6965 (55.9%) in
a hospital. The key factors for increased likelihood of inhospital death were receipt of inpatient palliative care (OR =
1.85), chemotherapeutic treatments in the last 30 days of life (OR = 1.61) and comorbid Congestive Heart Failure
(OR = 1.21), and Renal Disease (OR = 1.19). In contrast, higher care level (OR = 0.16), nursing home residency (OR = 0.
25) and receipt of outpatient palliative care (OR = 0.25) were associated with a reduced likelihood. All OR were
significant (p-values< 0.05). Expenditures in the last 30 days of life were significantly higher for patients with
inhospital death (€ 6852 vs. € 33,254, p-value< 0.0001).
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Conclusion: Findings suggest that factors associated with inhospital death often relate to previous contact with
hospitals like prior hospitalizations, and treatment of the tumour or comorbidities. Additionally, factors associated
with dying elsewhere relate to access to care settings which are more focused on palliation than hospitals. From
these results, we can derive that implementing tools like palliative care into tumour-directed therapy might help
patients make self-determined decisions about their place of death. This can possibly be achieved at reduced
economic burden for SHIs.
Keywords: Lung carcinoma, Place of death, End of life care, Terminal care, Routine data, Palliative care, Health care
supply structures,
Background
In Germany, around 51% of all-cause and tumour-re-
lated deaths occur in a hospital setting, whereupon
males (♂ 57% vs. ♀ 45%) and patients with tumours in
respiratory organs (60% vs. 50%) are affected above aver-
age [1]. Previous research has found that irrespective of
a cancer diagnosis, there is a preference for dying at
home or in a hospice; dying in a hospital setting is
favoured only by few (Gomes 2012, Gomes 2013, Pinzon
2011 and Higginson 2013) [2–5]. A palliative care setting
may help patients express preferences about their place
of death and their preferred treatment based on exten-
sive information. Thus, patients in palliative care settings
may more likely achieve their preferred end of life
choices which supposed to improve their Quality of life
(QoL) at the end of life. Although the number of inhos-
pital deaths has declined in recent years, there is still an
obvious discrepancy between the preferred and the ac-
tual place of death, especially in patients with respiratory
tumours. Furthermore, this patient group is of high
public health relevance, as respiratory tumours were the
fourth leading cause of death in Germany in 2015 [6].
Two studies from the US and the UK found that,
patients’ QoL at the end of life tends to be worse when
they die in a hospital compared to when they die
elsewhere, because they are more likely to experience
physical and emotional distress and feel less at peace [7,
8]. Owing to different framework conditions, generaliz-
ing findings from one health care system to another is a
sensitive issue. Of course, the results of the US-based
study might not be fully replicable in the German
setting, but since both systems are strongly “curatively”
oriented and pay subordinate attention to palliative care,
similar results can be expected for German populations.
Additionally, inpatient care at the end of life generates
higher expenditures than outpatient care as shown by
Gaertner et al. (2013) [9] and Schwarzkopf et al. (2015)
[10]. Thus, reducing the share of inhospital death in lung
cancer patients is in the interest of both the patients
concerned and health care service payers.
Costa (2014) published a systematic review on deter-
minants influencing the place of death of terminally ill
patients [11]. Interprofessional home palliative care and
early referral to palliative services, inter alia, increased
the number of home deaths. Based on these results, the
German palliative care system has been improved, as
Cremer-Schaeffer and Radbruch (2012) reported [12].
Since 2007, every German citizen has a legal claim to
palliative home care. Furthermore, palliative care was
implemented in educational programs for health pro-
fessionals and the number of hospices increased overall.
Consequently, Dasch et al. (2016) showed that the
number of inhospital deaths in German lung cancer
patients decreased between 2001 and 2011 (from 68,1%
to 60,3% in men and from 70,7% to 49,6% in women)
[1]. While trying to determine further factors influen-
cing the place of death, Escobar Pinzón et al. (2011)
found that nonworking relatives and a high care level
are associated with home deaths in the German general
population [4]. A study by Leak et al. (2013) describes
characteristics of 104 lung cancer patients dying in
emergency departments in North Carolina (USA) [13].
71% of those patients died on their first visit and 65%
of them were male. The most common chief complaint
was respiratory distress. Considerably more patients
(n = 143.627) were included in a UK nationwide study
of O’Dowd et al. (2016) [14]. They identified sex, in-
creasing age and social deprivation as factors associated
with inpatient death.
To our knowledge, there is no representative na-
tionwide study for a German population investigating
multiple factors related to inhospital death as well as
related to healthcare expenditures in German lung
cancer patients as of yet.
Therefore, our study aimed to improve the evidence
available by:
a) Defining factors related to inhospital death based
on statutory health insurance (SHI) claims data,
b) using logistic regression models to identify factors
associated with inpatient deaths, and
c) comparing healthcare expenditures in the terminal
phase between patients dying in a hospital and
patients dying elsewhere.
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Methods
Structure of the dataset
For our retrospective claims data analysis, we used
nationwide insurance claims data by the AOK Research
Institute (WIdO) [15] covering about 30% of the
German population. According to the German Guide-
lines for Secondary Data Analysis [16] ethical approval is
generally not required for this type of study. The
German Reporting Standards for Secondary Data
Analyses (STROSA) were considered in the preparation
and implementation of this study [17].
The basic dataset contained anonymized data of
17,478 patients diagnosed with lung cancer in 2009, with
patient-individual three-year follow-up (2009–2012). De-
tails about the sample collection are described elsewhere
[10]. Data included year and month of birth, sex, federal
state of residence, care level (reflecting impairment in
activities of daily living) and nursing home status over
the course of the disease. Additionally, we had informa-
tion on health care service utilization in the in- and out-
patient setting, as well as on corresponding diagnosis
codes (German International Classification of Diseases/
ICD-10-GM) and medical procedures undertaken (OPS/
German Version of the International Classification of
Procedures in Medicine respectively GONR/outpatient
billing codes).
Owing to data protection laws, date of death was only
provided per month. For the purposes of this analyses
we set date of death to the 15th of each month for any
individual observed. Thus, there is an admitted impreci-
sion of up to 2 weeks. To increase precision of date of
death we subsequently checked the discharge status of
hospital stays. Whenever death was documented here,
we replaced the fictive data of death (15th of x) by the
real date of death, which is date of discharge. Regarding
the remainders, we searched for service provision after
the 15th in the month of death. In case of service
provision in the second half of the month, this date was
assumed to be the date of death.
Sample selection
As we compared place of death (inhospital or elsewhere)
in our analysis, we excluded all patients who did not die
within the individual three year follow-up period (n =
3247). One individual was excluded due to implausible
data. To avoid a bias from patients with fulminant pre-
sentations and to focus on patients likely medically
stable enough to have a choice regarding their place of
death, we excluded patients who lived for less than
30 days after diagnosis (n = 1511). We further excluded
any patients who died during the hospital stay of diagno-
sis (n = 115) and those with an implausible date of death,
as they had claims for ambulant palliative treatments
after date of death (n = 23). There are two possible
reasons for claims of treatments after death. Firstly, out-
patient palliative care also includes grief counselling for
the relatives of the deceased. Secondly, as mentioned
above date of death in our study can differ from actual
date of death by a maximum of 2 weeks. Lastly, we ex-
cluded patients with unknown district type of residence
at the time of diagnosis (n = 124). Our final study sample
contained 12,457 patients (Fig. 1).
We assigned patients to the group inhospital death if
the discharge status was ‘death’ in the last hospital visit.
All other patients were assigned to the group of dying
elsewhere.
Factors related to inhospital death
We conducted a literature search in Pubmed in order to
identify factors possibly associated with inhospital death.
Search terms used included “place of death”, “end of life
care”, “quality at the end of life”, and “factors influencing
place of death” preferred for German lung cancer popu-
lations. We considered a potential association between
inhospital death and following factors: age at time of
death, gender, length of survival after diagnosis, nursing
home residency, need for care, residence in Eastern vs.
Western Germany, residence in rural vs. urban area,
palliative care, previous healthcare utilization and treat-
ment pattern, comorbidity burden and disease stage at
diagnosis [4, 11, 13, 14].
Survival was measured as months survived after diag-
nosis. Nursing home residency (yes / no) and need for
care defined as the patient’s care level refer to the last
quarter before death. At the time of data collection, the
German SHI system accounted for three care levels
reflecting the patient’s capabilities to independently
perform activities of daily living. The three levels of
dependency were distinguished by how often assistance
is needed and how long it takes a non-professional
caregiver to help the dependent person. Higher care
levels indicate increased need for assistance (i.e. greater
physical or psychological impairment1) [18]. Living in
Eastern or Western Germany as well as living in an
urban or rural district was defined based on the ZIP
code of the last documented residential address. We
used the district types defined by the Federal Institute
for Research on Building, Urban Affairs and Spatial De-
velopment for 2014, to classify the patients’ residential
area as urban (district type 1 and 2) or rural (district
type 3 and 4) [19].
Palliative care was included as a binary variable
indicating whether palliative care measurements were
administered at least once in an inpatient or outpatients
setting. Information for this came from claims relating
to palliative care codes (OPS for inpatient, GONR for
outpatient palliative care).
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We assessed previous healthcare utilization by calcu-
lating the number of days patients spent in a hospital,
the number of outpatient hospital visits and of out-
patient doctor visits (based on the number of days with
a claim for a GONR) between diagnosis and death. To
factor in collinearity with survival time we divided all
those aspects by survival in months, resulting in
utilization of healthcare by month survived.
To best possibly account for tumour stage at diagnosis
–which is not documented within claims data– we used
the type of tumour-directed therapy patients received
and the location of metastases at baseline. We grouped
patients using inpatient and outpatient ICD-10, OPS,
billing and ATC codes into ‘no tumour-directed therapy’,
‘surgical resection’, ‘radiotherapy’, ‘chemotherapy’ and
combinations of chemotherapy, radiotherapy and surgi-
cal resection. We identified patients with metastases at
baseline using inpatient and verified outpatient ICD 10
codes in the quarters before and after the diagnosis of
lung cancer and grouped them according to location;
into thoracic, cerebral and bone metastases.
To reflect treatment intensity at the end of life, we re-
ported chemotherapy given in the last 30 days before death
as binary variable. This indicator of aggressive treatment
has been used previously in end-of-life research [20].
To assess the patients’ comorbidity burden, we calcu-
lated the Charlson comorbidity index using the coding
algorithm described by Sundararajan et al. (2004) [21]
on all ICD-10 codes in claims in the 2 years prior to the
diagnosis of lung cancer and included the distinct Charl-
son conditions as binary variables (comorbidity yes /
no). As slight modifications from the initial algorithm,
lung cancer was excluded from the condition ‘cancer’.
Furthermore, we disregarded the condition ‘metastatic
carcinoma’ to avoid a multicollinearity issue with the
variable metastases location at baseline.
Economic implications
To assess the economic implications of inhospital death
we calculated expenditures for the health insurance
company in the last 30 days before death. We compared
total all-cause expenditures for hospitalizations, doctor
visits and medications between patients with inhospital
death to those who died elsewhere.
Statistical methods
To investigate potential differences between lung cancer
patients dying in a hospital and those dying elsewhere,
we compared means, standard derivations (SD) medians
and frequencies of basic variables like, gender, age and
need for care. Categorical variables were compared using
the χ2-test. Only age was approximately normally dis-
tributed (visual inspection) and compared using t-test
(pooled test for equal variances). All other categorical
Fig. 1 Patient flow diagram
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variables were compared with Wilcoxon U-test for non-
normal distributions. We compared survival trends of both
groups via Kaplan-Meier curves and Log-Rank tests.
To examine the relationship between the related
factors described above and inhospital death we used a
multivariate logistic regression model and chose LASSO
(“least absolute shrinkage and selection operator”) as the
selection method [22]. LASSO selection combines some
of the favourable properties of stepwise regression (ease
of interpretation) and ridge regression (robustness) [22]
while additionally performing better concerning multi-
collinearity [23, 24]. The first part of the LASSO loss
function is equal to an ordinary least square regression,
whereas the second part constrains the absolute value of
the sum of the regression estimates by the parameter. It
can be written as
LLasso β1;…; βp
 
¼ Y−
Xp
j¼1
X jβ j


2
þ λ
Xp
j¼1
β j


where L is the loss function, X is an n × p design matrix
for predictors, Y is an n × 1 vector of responses, β is a
p × 1 vector of regression coefficients, and λ ≥ 0 is the
regularization parameter that controls the degree of
shrinkage. Because the penalty term ðλPpj¼1 jβ jjÞ is
based on the sum of the absolute values of the regres-
sion estimates, some estimates can be shrunken to
exactly zero, which results in their exclusion from the
model. That enables LASSO to be used for selection of
predictor variables [25]. The LASSO loss function is not
differentiable because of the unknown parameter λ.
Thus, we used the method proposed by Nesterov (2013)
to minimize the function while optimizing λ [26]. Age
and sex were considered as pre-fixed covariates. To cal-
culate odds ratios (ORs), 95%-confidence intervals (CIs)
and p-values, we ran a logistic regression model with the
covariates identified by LASSO selection. In this regard,
it should be noted that all variables chosen by LASSO
selection have an important influence on the outcome
variable, irrespective of their statistical significance
within the subsequent logistic regression model.
As expenditures did not show a normal Gaussian dis-
tribution using linear regression (OLS) was not possible.
Therefore, we used a Generalized Linear Model (GLM)
with gamma distribution and log link function. This kind
of model is able to handle data that are right-skewed
and eliminates heteroscedasticity [27]. The derivate of
the parameter estimates from gamma regression repre-
sent the additive effect (in expenditures) that a change
in this variable would cause. To interpret these results
more easily, healthcare expenditures were reported as
recycled predictions with confidence intervals and
p-values. Recycled predictions are used to understand
the marginal effect of independent variables on a
dependent variable. They are obtained from the gamma
regression model by averaging predicted scores, after
fixing the value of one independent variable (either
inhospital death, or death elsewhere), and using ob-
served values on the remaining independent variables.
The recycled predictions then provide adjusted means
for both groups [28]. All recycled prediction models
were adjusted by the factors identified as being associ-
ated with inhospital death earlier. The parameter esti-
mates obtained from this gamma GLM are provided as
Additional file 1.
Confidence intervals and p-values of the adjusted
means and difference were based on non-parametric
bootstrapping (1000 bootstrap repetitions, percentile
method). We used a significance level of 5% for all
analyses.
To examine the robustness of the model we ran three
sensitivity analyses (SA). For SA1 we extended the defin-
ition of inhospital death to include patients who were
discharged from the hospital in the week before death
and spent at least 2 days in the hospital in that week
(additional 825 patients in inhospital death group). We
chose the last week of life because it is defined as phase
of death and we assumed that hospitalization in that
final phase might correlate particularly strong with a de-
creased QoL [29]. Because our definition of inhospital
death did not reflect whether a patient died on a general
ward or on a palliative ward we ran SA2. Here, we
reassigned 572 patients with inhospital death who had
palliative treatments during the hospital stay of death to
the group with death elsewhere. To avoid missing
important information about patients with fulminant
presentation (death during the first 30 days after diagno-
sis) we did not exclude these patients in SA 3 and
performed the analysis with a sample of 13,090 patients.
All statistical analyses were performed using SAS ver-
sion 9.4. Figures and tables were created with Microsoft
Word, Power Point and Excel.
Results
Patient population and univariate analysis of factors
related to inhospital death
Of the final study sample, 6965 individuals (55.9%) died
in a hospital (Table 1). Patients with inhospital death
were significantly younger than patients who died out-
side a hospital. Most of the patients were male (71.7%)
with a significantly higher proportion of males in the
inhospital death group. The residential setting was com-
parable in both groups regarding regional (Eastern vs.
Western Germany) as well as structural (urban vs. rural)
aspects. Nursing home residency was significantly less
common in the inhospital death group, even though
only few patients (7.7%) lived in a nursing home at all.
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Further, need for care was significantly less severe in
those dying in a hospital. Mean Charlson comorbidity
score did not differ significantly between the two groups.
Patients dying in a hospital significantly more often had
thoracic metastases (34.5% vs. 32.8%), other metastases
locations did not differ.
Median survival was lower in patients dying in the
hospital and the log-rank test showed significantly differ-
ent survival between the two groups (Fig. 2).
Patients dying in a hospital were hospitalized signifi-
cantly more often (10.9 vs. 8.4 days per month survived,
p-value < 0.0001) and visited outpatient doctors signifi-
cantly more frequently (3.1 vs. 2.8 visits per month
survived, p-value < 0.0001).
The proportion of patients with inpatient palliative
care was significantly higher in patients with inhospital
death (18.0% vs. 13.4%, p-value < 0.0001) and the pro-
portion of patients with outpatient palliative care was
significantly higher in patients who died elsewhere (7.7%
vs 1.6%, p-value < 0.0001).
The proportion of patients receiving chemotherapy in
the last 30 days of life was significantly higher in the
inhospital death group (30.0% vs. 16.7%, p-value <
0.0001). Overall, almost one-fifth of patients did not
receive any tumour-directed therapy between diagnosis
and death (n = 2.124, 17.1%). The proportion of patients
not receiving cancer-directed therapy was significantly
lower in the inhospital death group (12.9% vs 22.4%,
p-value < 0.0001). Descriptive statistics of healthcare
utilization, palliative care and therapy are displayed
in Table 2.
Regarding comorbidity burden, dementia was signifi-
cantly less prevalent in the inpatient death group,
whereas the prevalence of peripheral vascular disease,
diabetes with complications and renal disease was
significantly higher (Fig. 3).
Multivariate analysis of factors related to inhospital death
The LASSO method selected the following as factors re-
lated to inpatient death: length of survival in months,
nursing home residency, care level, number of hospital
days, inpatient and outpatient palliative care, chemother-
apy in the last 30 days of life, presence of congestive
heart failure (CHF), and renal disease, as well as cerebral
metastases (Table 3). Longer survival since diagnosis
increased the odds of inhospital death. Nursing home
residency, and increasing need for care reflected by
higher care levels decreased the odds. Having spent
Table 1 Description of the study sample
Entire sample Inhospital death No Inhospital death p-valuec
n (%) 12,457 (100) 6965 (55.9) 5492 (44.1)
Mean age at death (SD) 69.9 (10.0) 68.8 (10.0) 71.4 (9.9) < 0.0001
Sex
Male N (%) 8930 (71.7) 5070 (72.8) 3860 (70.3) 0.002
Survival
Median survival in months 7 7 8 < 0.0001
Living in a nursing home a (%) 958 (7.7) 188 (2.7) 770 (14.0) < 0.0001
Care level a
No care level N (%) 4958 (39.8) 3769 (54.1) 1189 (21.7) < 0.0001
1 N (%) 2451 (19.7) 1324 (19.0) 1127 (20.5) 0.0351
2 N (%) 3416 (27.4) 1376 (19.8) 2040 (37.1) < 0.0001
3 N (%) 1632 (13.1) 496 (7.1) 1136 (20.7) < 0.0001
State
Western Germany N (%) 9724 (78.1) 5478 (78.7) 4246 (77.3) 0.0732
Urban district b N (%) 7829 (62.9) 4380 (62.9) 3449 (62.8) 0.922
Mean Charlson Comorbidity Score (SD) 3.77 (2.65) 3.81 (2.66) 3.72 (2.63) 0.0777
Body regions with Metastases
Cerebal N (%) 2271 (18.2) 1237 (17.8) 1034 (18.8) 0.1256
Bones N (%) 2845 (22.8) 1630 (23.4) 1215 (22.1) 0.0912
Thoracic N (%) 4207 (33.8) 2406 (34.5) 1801 (32.8) 0.0402
a Data of the last quarter before death were used
b Urban district is based on the district types defined by the Federal institute for Research on Building, Urban Affairs and Spatial Development for 2014. Urban
district contains district type 1 and 2, the reference category rural district contains district type 3 and 4
cp-values were calculated with t-test for age at death, Wilcoxon U-test for Charlson Comorbidity Score and Chi2 test for sex, living in a nursing home, care level,
state and urban district
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Fig. 2 Kaplan-Meier-Curve to compare the survival of patients depending on place of death
Table 2 Descriptive statistics of healthcare utilization, palliative care and therapy
Entire sample Inhospital death No Inhospital death p-valuec
n (%)
Healthcare utilization a
12,457 (100) 6965 (55.9) 5492 (44.1)
Number of hospital days (SD) 9.8 (8.2) 10.9 (8.7) 8.4 (7.3) < 0.0001
Number of outpatient doctor visits (SD) 3.0 (2.4) 3.1 (2.6) 2.8 (2.2) < 0.0001
Number of outpatient hospital visits (SD) 0.01 (0.1) 0.01 (0.1) 0.02 (0.1) 0.0559
Palliative Care
Inpatient palliative care N (%) 1994 (16.0) 1256 (18.0) 738 (13.4) < 0.0001
Outpatient palliative care N (%) 2388 (4.3) 111 (1.6) 425 (7.7) < 0.0001
Chemotherapy in last 30 days of life (%) 3009 (24.2) 2090 (30.0) 919 (16.7) < 0.0001
Treatment b
No treatment N (%) 2124 (17.1) 896 (12.9) 1228 (22.4) < 0.0001
Chemotherapy N (%) 2990 (24.0) 1745 (25.1) 1245 (22.7) 0.002
Radiotherapy N (%) 967 (7.8) 512 (7.4) 455 (8.3) 0.0532
Surgery N (%) 715 (5.7) 421 (6.0) 294 (5.4) 0.0996
Chemotherapy and Radiotherapy N (%) 3169 (25.4) 1867 (26.8) 1302 (23.7) < 0.0001
Chemotherapy and Surgery N (%) 1016 (8.2) 632 (9.1) 384 (7.0) < 0.0001
Radiotherapy and Surgery N (%) 301 (2.4) 158 (2.3) 143 (2.6) 0.2263
All three types N (%) 1175 (9.4) 734 (10.5) 441 (8.0) < 0.0001
a Healthcare utilization by month survived between diagnosis and death
b Information if patients received this combination of treatments at any time of the observation period. Number or order of treatments was not considered
cp-values from Wilcoxon U-test for healthcare utilization, and from Chi2 test for treatment and palliative care
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more days in a hospital and receiving inpatient palliative
care increased the likelihood for inhospital death
whereas receiving outpatient palliative care resulted in a
lower risk for inhospital death. If a patient received
chemotherapy in the last 30 days of life, he was more
likely to die in a hospital setting. Patients with CHF, or
renal disease had an increased risk of inhospital death.
Furthermore, patients with cerebral metastases had a
decreased risk of inhospital death.
Multivariate analysis of expenditures
All-cause total costs were significantly higher for
patients dying in a hospital (€ 6852 vs. € 3.254, p-value
< 0.0001). Hospitalizations made up the biggest part of
expenditures and were significantly higher in patients
with inhospital death (€ 5895 vs. € 2321, p-value <
0.0001). Expenditures for doctor visits were significantly
higher in patients who did not die in a hospital (€ 358
vs. € 245, p-value < 0.0001), as were expenditures for
medications (€ 691 vs. € 585, p-value < 0.0001).
Sensitivity analyses
The results of SA1 (Additional file 2) and the main ana-
lyses were similar, however the LASSO method did not
result in an inclusion of renal disease as an important
factor anymore. The results of SA2 (Additional file 2)
and the main analyses differed in two aspects. First,
chronic pulmonary disease (CPD) was selected as im-
portant factor additionally, increasing the odds of inhos-
pital death. Second, inpatient palliative care now
decreased the likelihood of inhospital death.
The model in SA3 was almost the same as in the main
analysis, some effect sizes changed in decimal places only.
Discussion
In our study, we sought to identify factors related to
inhospital death in German lung cancer patients. We
found that especially the patients’ age and frailty, as
measured in the need for care and nursing home resi-
dency, were important factors related to not dying in a
hospital. In addition, patients with cerebral metastases
had a decreased risk of inhospital death. The utilization
of outpatient palliative care also reduced the likelihood
of inhospital death but receiving inpatient palliative care
increased the likelihood of inhospital death. Further-
more, a higher number of days spent in a hospital, CHF
and renal disease, as well as receiving chemotherapy in
the last 30 days of life were associated with an increased
risk of inpatient death.
Total healthcare expenditures were about twice the
expenditures of dying elsewhere, with expenditures for
hospitalizations predominantly responsible for these
Fig. 3 Prevalence of Charlson comorbidity groups depending on place of death
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differences. Although expenditures for outpatient care
and medications were higher in patients not dying in the
hospital, the sum of these differences were negligible
compared to the differences in inpatient expenditures.
Evidence, in which direction age affects inhospital
death is inconclusive: Dasch et al. found a negative asso-
ciation for the general population in a North Rhine-
Westphalia-based study (< 60 versus > 80 years: OR 1.41,
p-value 0.001) [30], but O’Dowd et al. observed a posi-
tive association among lung cancer patients in the UK
(> 85 year vs. 70–74 years OR 1.16; 95% CI 1.08–1.24)
[14]. Finally, Escobar Pinzón et al. (2011) found no
association at all between age and place of death in a
population of Rhineland-Palatinate, however this study
was not focused on lung cancer patients but referred to
the general population [4]. We believe that our observa-
tion of negative association is plausible: Younger patients
may be subject to more aggressive inpatient therapy.
Therefore, their primary clinical relationship is rather with
an oncologist than with a palliative care team. Moreover,
they might have more social/familial obligations than
older patients and death at home may not be desirable if
they have a young family at home. Consequently, younger
patients have an increased risk of inpatient death.
Longer survival after diagnosis increased the risk of
inhospital death. This was a surprising result at first as
we assumed that patients with shorter survival have less
time to come to terms with impending death, and
therefore to organize their final days in a preferred and
comfortable place. However, if a patient is diagnosed in
a late stage of the disease the focus of care is more likely
to be on palliation and organizing end-of-life care rather
than curative therapy. In line with that, patients with
cerebral metastases at time of diagnosis died in the
hospital less frequently.
In our study nursing home residency was associated
with a reduced likelihood of dying in a hospital. This
might be explained by the fact that continuous nursing
care — as often required at end of life — is already avail-
able in this setting, whilst it can often not be guaranteed
in an ambulatory setting. Even though dying in a nursing
home or in a hospice is not the same as dying at home,
most patients prefer those places to hospitals [2]. Rela-
tives who are not able to arrange care of the patients at
home due to financial or other reasons, thus should be
supported more relating organization of accommodation
in a hospice or a palliative care facility in order to in-
crease the patient’s QoL during the last days. Wye et
al. (2014) describe that arranging care outside the
hospital is a very tough task for the relatives [31]. For
this reason, the UK has implemented end of life care
services, which provide nurses who support relatives
with organizational services, as well as assistance with
decision-making. These nurses are supposed to offer
time for conversations with the patients and the rela-
tives about death, as well as the practical aspects of
caring for the dying. This concept works especially
for cancer patients who are close to death and should
be considered as a developing concept to further im-
prove end of life care in Germany. Actually, at the
time this study was conducted, there was study on-
going to evaluate establishing a system of ‘social care
nurses’ in cancer therapy in Germany funded by the
German Ministry of health.
Our study indicated that patients with lower care
levels are more likely to die in a hospital. Escobar Pinzón
et al. (2011) found similar results in his study (care level
3 vs no care level: OR (death elsewhere vs inhospital
death) 4.95, p-value < 0.0001) [4]. The higher the care
level the higher the need for support in various aspects
of everyday life. Thus, comprehensively dealing with the
organization of the required care has already taken
place. If a home-care setting for a person with high
nursing needs has been organized previously, it is far
easier to enable the patients dying outside a hospital –
as hospitalization is necessary less frequently, and rela-
tives are able to handle complications outside a hospital
(with assistance of professionals).
Table 3 Results of the logistic regression
OR a, b 95% CI a, c p-value
Age at death 0.985 0.98–0.989 < 0.0001
Sex
Male vs female 0.95 0.87–1.04 0.2533
Survival in months 1.01 1.006–1.02 < 0.0001
Living in a nursing home 0.25 0.21–0.30 < 0.0001
Care level (reference = no care level)
1 0.47 0.42–0.53 < 0.0001
2 0.26 0.24–0.29 < 0.0001
3 0.16 0.14–0.19 < 0.0001
Healthcare utilisation
Number of hospital days d 1.04 1.036–1.05 < 0.0001
Palliative Care
Inpatient palliative care 1.85 1.66–2.08 < 0.0001
Outpatient palliative care 0.25 0.20–0.32 < 0.0001
Chemotherapy in last 30 days of life 1.61 1.46–1.77 < 0.0001
Charlson Comorbidities Groups
Congestive Heart Failure 1.21 1.11–1.33 < 0.0001
Renal Disease 1.19 1.08–1.32 0.0006
Body regions with Metastases
Cerebral metastases 0.86 0.77–0.96 0.0050
a Values are rounded to two decimals except if they would be rounded to
exactly 1 then they are rounded to three decimals
b Odds ratio
c 95% confidence interval
d Healthcare utilization by month survived between diagnosis and death
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According to our study, CHF and renal diseases
increased the probability of inhospital death. These
comorbid conditions tend to require intense treatments
and are associated with a high likelihood of complica-
tions. Managing these complications often requires fur-
ther inpatient hospital care [32]. However, it should be
examined whether it is possible to further train formal
and informal care-givers to manage these conditions
outside the hospital.
If a patient in our study received inpatient palliative
care, he was more likely to die in a hospital setting. This
finding was unsurprising as inpatient palliative care is
administered in a hospital for example on a palliative
care ward. Our SA 2 supports this assumption as in this
analysis we regrouped patients from the inhospital death
group, if they had an inpatient palliative care treatment
in the hospital stay of death. Resulting in the effect of
inpatient palliative care changing direction and now
reducing the likelihood of inpatient death.
Given, that outpatient palliative care was per se pro-
vided on a low level among patients of the inhospital
death group, a conclusive interpretation of these results
is limited to some extent. By trend, our analyses support
the study of Purdy et al. (2015), which reported that
patients receiving outpatient palliative care for a longer
duration were less likely to die in a hospital. Patients
and relatives using palliative care have usually already
confronted the fact of impending death. Most families
feel overburdened in this situation. The providers of
palliative care are in a better position to assist the family
with decision-making and to help them with enabling
the patient’s death in a preferred place – mainly because
there is sufficient time and opportunity for such conver-
sations. Furthermore, palliative care providers have a
broad base of knowledge about the health care system as
well as local supply structures. In addition, engaging
with outpatient palliative care may define a population
who are more determined to die at home. Purdy et al.
(2015) [33] demonstrated that an end of life coordin-
ation centre that aims to help patients under palliative
care be cared for in their preferred place, can reduce the
number of inhospital deaths significantly (OR 0.33,
p-value < 0.001).
In contrast to receiving palliative care, the administra-
tion of chemotherapy in the last 30 days of life was
associated with an increased likelihood of inhospital
death. Receiving chemotherapy shortly before death can
be considered as an aggressive treatment and deemed
undesirable by some clinicians [34, 35], even though it
needs to be kept in mind that palliative care could to
some extent also include chemo-therapeutic measures.
That these patients more often die in a hospital could be
explained by the close relationship between the patient
and the oncologist who is often located in a hospital.
Furthermore, death might be associated with the treat-
ment itself while in the hospital.
Similar reasons could play into the finding that
patients with a higher number of hospital days also have
a higher likelihood of inpatient death. A higher number
of hospitalizations may indicate a more aggressive or
longer tumour-directed treatment. Therefore, patients
have an established relationship with the hospital and its
clinicians and associate them rather than a palliative care
team with the primary point of contact.
Despite higher comorbidity burden, patients in the
inhospital death group were less frail as measured in
care level and nursing home residency. Therefore, we
can deduct that it’s not the patients’ frailty that has an
impact on the place of death as these patients are
already cared for at diagnosis, but more importantly
specific comorbidities. Therefore, these comorbidities
are important aspects to consider when lung cancer is
diagnosed.
As expected, we found that expenditures for inpatient
care were around double in the inhospital death group.
However importantly, we could see that the excess costs
in the outpatient sector for patients who did not die in
the hospital were almost negligible. From this, we can
conclude that not only costs for hospitalizations are
much higher, but also additional expenditures for
outpatient care are extremely low.
Thus, extending outpatient palliative care services as it
currently happens in Germany will probably create a
win-win situation for patients and the SHI system, since
the expected decline in expenditures for inpatient care
would compensate for the additional expenses in the
outpatient sector. Our results are supported by the stud-
ies of Faßbender (2005) [36] and Smith et al. (2012) [37]
who found that palliative care might have a cost-cutting
effect because of fewer therapeutic interventions not
primarily aiming at improving QoL for terminally ill
patients. Thereby the need for inpatient treatments
might be reduced and patients remain in a stable condi-
tion while still receiving sufficient medical and
non-medical care.
Most limitations in our study stem from the use of
claims data, which are primarily documented by health-
care providers for billing purposes with health insurance
funds. The exact place of death is not important for
these parties and is therefore not documented. This is
the reason that within this study we have only been able
to distinguish between inhospital death and death
elsewhere. We do not know if patients in the inhospital
death group died on a palliative ward or on a normal
ward, nor can we differentiate between various places of
death outside a hospital such as a hospice or the family
home. Owing to data protection laws, data contained
only year and month of death for those who died in an
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outpatient setting. We used rules to define a more valid
date of death but there are still possible differences to
the actual date of death of up to 2 weeks for each indi-
vidual. As O’Malley et al. (2005) described, the coding of
ICD- and OPS-codes is a source of error in itself [38]
which can e.g. arise out of unintentional and intentional
coder errors, such as misspecification, unbundling, and
up-coding. This should be considered when interpreting
variables based on those codes like Charlson comorbid-
ity groups. For historical reasons, the average income
and the family structure of AOK-insured people may
differ from the general German population. When there
was no free choice of health insurance provider, the
AOK as a Local Health Care Funds insured the general
population (workers, retirees, family members) in
contrast to company-provided health insurance funds,
which for example insured predominantly persons with
higher incomes and who tends to be healthier. Even now
when all members of the population are in the position
to choose their own health insurance provider, this
structure is still visible. However, Jaunzeme et al. (2013)
have shown that these differences are small enough to
assume that the population of AOK-insured and
herewith our results are representative for the German
resident population [39].
Our study represents the first nationwide examination
of factors possibly related to inhospital death in German
lung cancer patients such as the patients’ care needs,
comorbidity burden, lung cancer-related treatments, and
regional aspects. More importantly, we could provide
expenditures for inhospital death not only as total but
also for different aspects of care and therefore provide
evidence that investments in palliative care can never-
theless reduce expenditures in total. As an innovative
methodological approach, we applied the LASSO selec-
tion method which combines the easy interpretability
and robustness. LASSO selection has been shown to
outperform other selection methods like stepwise selec-
tion [40]. Finally, our analyses are automatically based
on a multicentre study, whereby biases resulting from
specific documentation rules and approaches of single
healthcare providers are avoided. Thus, we are con-
vinced that these analyses create a sound starting point
for conditions that need to be considered when trying to
create an environment supporting terminally ill-patients
to make a more self-determined decision on where to
spend their last days of life.
Conclusion
This study provides further evidence about factors re-
lated to inhospital death in German lung cancer patients.
Findings suggest that factors associated with inhospital
death often relate to previous contacts with hospitals.
This includes prior hospitalizations, tumour-directed
treatment and treatment of comorbidities. Additionally,
factors associated with dying elsewhere relate to access
to other care settings than hospitals where therapy is
focused more on palliation. From these results we can
implicate that an early or earlier integration of palliative
care into tumour-directed therapy might be a useful tool
in helping patients to make informed decisions in the
last phase of their life, by using established relationships
e.g. with the oncologist. Additionally, further expanding
the palliative supply network, can be achieved while still
reducing costs for SHIs.
Endnotes
1Care level I: People who need assistance with
personal hygiene, feeding or mobility for at least two
activities from one or more areas at least once a day,
and who additionally need help in the household several
times a week for at least 90 min a day with 45 min
attributable to basic care.Care level II: People who need
assistance in at least two basic activities of daily living
(ADLs) at least three times a day at various times and
additional help in I ADLs several times a week for at
least 3 h a day, with 2 h attributable to basic care.Care
level III: People who need assistance in at least two
ADLs around the clock and additional help in an IADL
several times a week for at least 5 h per day, with 4 h
attributable to basic care.
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